文献速递慢性肾脏病

尿液和血浆代谢物与慢性肾脏病队列中肾衰竭和死亡的关联

Associations of Urine and Plasma Metabolites With Kidney Failure and Death in a Chronic Kidney Disease Cohort.
PubMed 文献 · Am J Kidney Dis · 2024-05-28

该研究在GCKD队列中前瞻性分析尿液和血浆代谢物与肾衰竭、复合肾脏终点及死亡的关联,并利用ARIC研究外部验证。中位随访6.5年,发现182种独特代谢物与结局显著相关,其中血浆羟天冬酰胺与肾衰竭关联最强(HR 1.95),88%的关联在外部验证中方向一致。

要点

  • 血浆羟天冬酰胺与肾衰竭关联最强,HR为1.95。
  • 182种代谢物与肾衰竭、复合肾脏终点或死亡显著相关。
  • 88%的代谢物-结局关联在外部验证中方向一致。

核心结论

  • 在CKD患者中,多种尿液和血浆代谢物与肾衰竭、复合肾脏终点或死亡存在关联,部分为既往未报道的关联。

研究设计与样本

  • 前瞻性代谢组关联研究,纳入GCKD研究中5088例(尿液分析)和5144例(血浆分析)CKD患者,并在ARIC研究中进行外部验证。

主要发现

  • 中位随访6.5年,500人发生肾衰竭,1083人发生复合肾脏终点,680人死亡。
  • 182种独特代谢物中,30种与肾衰竭显著相关,49种与复合肾脏终点显著相关,163种与死亡显著相关。
  • 血浆羟天冬酰胺与肾衰竭关联最强(HR 1.95,95%CI 1.68-2.25)。
  • 一种未命名代谢物在血浆和尿液中均与肾衰竭、复合肾脏终点和死亡显著相关。
  • 外部验证中88%的代谢物与肾衰竭或复合肾脏终点的关联方向一致,18种代谢物的关联为既往未报道。

临床怎么用

  • 这些代谢物关联可为识别CKD进展高风险患者提供候选生物标志物,但需进一步验证。

局限性

  • 观察性研究,代谢物为单时间点半定量测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Biomarkers that enable better identification of persons with chronic kidney disease (CKD) who are at higher risk for disease progression and adverse events are needed. This study sought to identify urine and plasma metabolites associated with progression of kidney disease. STUDY DESIGN: Prospective metabolome-wide association study. SETTING & PARTICIPANTS: Persons with CKD enrolled in the GCKD (German CKD) study with metabolite measurements, with external validation within the ARIC (Atherosclerosis Risk in Communities) Study. EXPOSURES: 1,513 urine and 1,416 plasma metabolites (Metabolon Inc) measured at study entry using untargeted mass spectrometry. OUTCOMES: Main end points were kidney failure (KF) and a composite kidney end point (CKE) of KF, estimated glomerular filtration rate<15mL/min/1.73m2, or a 40% decrease in estimated glomerular filtration rate. Death from any cause was a secondary end point. After a median of 6.5 years of follow-up, 500 persons had experienced KF, 1,083 had experienced the CKE, and 680 had died. ANALYTICAL APPROACH: Time-to-event analyses using multivariable proportional hazard regression models in a discovery-replication design with external validation. RESULTS: 5,088 GCKD study participants were included in analyses of urine metabolites, and 5,144 were included in analyses of plasma metabolites. Among 182 unique metabolites, 30 were significantly associated with KF, 49 with the CKE, and 163 with death. The strongest association with KF was observed for plasma hydroxyasparagine (HR, 1.95; 95% CI, 1.68-2.25). An unnamed metabolite measured in plasma and urine was significantly associated with KF, the CKE, and death. External validation of the identified associations of metabolites with KF or the CKE revealed directional consistency for 88% of observed associations. Selected associations of 18 metabolites with study outcomes have not been previously reported. LIMITATIONS: Use of observational data and semiquantitative metabolite measurements at a single time point. CONCLUSIONS: The observed associations between metabolites and KF, the CKE, or death in persons with CKD confirmed previously reported findings and also revealed several associations not previously described. These findings warrant confirmatory research in other study cohorts. PLAIN-LANGUAGE SUMMARY: Incomplete understanding of the variability of chronic kidney disease (CKD) progression motivated the search for new biomarkers that would help identify people at increased risk. We explored metabolites in plasma and urine for their association with unfavorable kidney outcomes or death in persons with CKD. Metabolomic analyses revealed 182 metabolites significantly associated with CKD progression or death. Many of these associations confirmed previously reported findings or were validated by analysis in an external study population. Our comprehensive screen of the metabolome serves as a valuable foundation for future investigations into biomarkers associated with CKD progression.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Steinbrenner I, Schultheiss UT, Bächle H, et al. Associations of Urine and Plasma Metabolites With Kidney Failure and Death in a Chronic Kidney Disease Cohort. Am J Kidney Dis. 2024. PMID: 38815646. doi:10.1053/j.ajkd.2024.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。